Philipp Wirth
Internal Medicine · Pinehurst, NCNPI 1194915389
Payments from drug & device makers
Across 506 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$1K
- Novo Nordisk$665
- Lilly USA, LLC$551
- GSK$528
- AbbVie$418
- plus $3K from 41 others
What the payments were for
- Food & beverage$7,97999%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,081 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 198 | $303,803 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 221 | $165,798 |
| EliquisApixaban | 142 | $149,122 |
| JardianceEmpagliflozin | 117 | $119,658 |
| RybelsusSemaglutide | 56 | $104,672 |
| FarxigaDapagliflozin Propanediol | 74 | $77,665 |
| XareltoRivaroxaban | 50 | $69,639 |
| TrulicityDulaglutide | 45 | $61,795 |
| GlyxambiEmpagliflozin/Linagliptin | 33 | $56,465 |
| JanuviaSitagliptin Phosphate | 47 | $55,135 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $49,365 |
| LinzessLinaclotide | 53 | $48,056 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $31,280 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $29,881 |
| InvokanaCanagliflozin | 26 | $26,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $665 | $408,474254 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr | $137 | $206,003168 claims |
| PfizerEliquis, Nurtec Odt, Prempro, Paxlovid | $1,202 | $185,175195 claims |
| GSKTrelegy Ellipta | $528 | $165,798221 claims |
| MerckJanuvia, Janumet | $155 | $104,50091 claims |
| Johnson & JohnsonXarelto, Invokana | $167 | $95,74376 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $551 | $83,88061 claims |
| AstraZenecaFarxiga | $1,291 | $77,66574 claims |
| AbbVieLinzess | $418 | $48,05653 claims |
| AmgenProlia | $219 | $21,69713 claims |
| Astellas Pharma US IncMyrbetriq | $327 | $14,41818 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $118 | $10,67220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Pinehurst
- Michael SoboeiroPinehurst$827K
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.